Gary Raskob to Patient Discharge
This is a "connection" page, showing publications Gary Raskob has written about Patient Discharge.
Connection Strength
1.615
-
Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients. J Am Coll Cardiol. 2020 06 30; 75(25):3140-3147.
Score: 0.674
-
Benefit-Risk Assessment of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness. J Am Heart Assoc. 2022 10 18; 11(20):e026229.
Score: 0.197
-
Benefit-Risk of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness: Pooled Analysis From MAGELLAN and MARINER. J Am Heart Assoc. 2021 11 16; 10(22):e021579.
Score: 0.185
-
Prevention of Venous Thromboembolism in Hospitalized Medically Ill Patients: A U.S. Perspective. Thromb Haemost. 2020 Jun; 120(6):924-936.
Score: 0.168
-
New paradigms in venous thromboprophylaxis of medically ill patients. Thromb Haemost. 2017 08 30; 117(9):1662-1670.
Score: 0.137
-
The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE. Design, rationale, and clinical implications. Thromb Haemost. 2016 06 02; 115(6):1240-8.
Score: 0.124
-
Association of Bleeding Severity With Mortality in Extended Thromboprophylaxis of Medically Ill Patients in the MAGELLAN and MARINER Trials. Circulation. 2022 05 10; 145(19):1471-1479.
Score: 0.048
-
Rivaroxaban for extended thromboprophylaxis in acutely ill medical patients 75 years of age or older. J Thromb Haemost. 2021 11; 19(11):2772-2780.
Score: 0.046
-
Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness. N Engl J Med. 2018 Sep 20; 379(12):1118-1127.
Score: 0.037